- Home
- SUGP vs AIMD Comparison
SUGP vs AIMD Comparison
Compare SUGP & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- AIMD
- Stock Information
- Founded
- SUGP 1998
- AIMD 1984
- Country
- SUGP Hong Kong
- AIMD United States
- Employees
- SUGP N/A
- AIMD N/A
- Industry
- SUGP
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- SUGP
- AIMD Health Care
- Exchange
- SUGP NYSE
- AIMD Nasdaq
- Market Cap
- SUGP 8.9M
- AIMD 8.2M
- IPO Year
- SUGP 2024
- AIMD N/A
- Fundamental
- Price
- SUGP $0.80
- AIMD $0.66
- Analyst Decision
- SUGP
- AIMD
- Analyst Count
- SUGP 0
- AIMD 0
- Target Price
- SUGP N/A
- AIMD N/A
- AVG Volume (30 Days)
- SUGP 30.6K
- AIMD 392.9K
- Earning Date
- SUGP 07-21-2025
- AIMD 08-04-2025
- Dividend Yield
- SUGP N/A
- AIMD N/A
- EPS Growth
- SUGP 1.19
- AIMD N/A
- EPS
- SUGP 0.11
- AIMD N/A
- Revenue
- SUGP $23,446,259.00
- AIMD $106,207.00
- Revenue This Year
- SUGP N/A
- AIMD N/A
- Revenue Next Year
- SUGP N/A
- AIMD N/A
- P/E Ratio
- SUGP $7.62
- AIMD N/A
- Revenue Growth
- SUGP 11.29
- AIMD 13.38
- 52 Week Low
- SUGP $0.52
- AIMD $0.40
- 52 Week High
- SUGP $3.25
- AIMD $1.17
- Technical
- Relative Strength Index (RSI)
- SUGP 49.03
- AIMD 60.11
- Support Level
- SUGP $0.76
- AIMD $0.62
- Resistance Level
- SUGP $0.86
- AIMD $0.80
- Average True Range (ATR)
- SUGP 0.08
- AIMD 0.07
- MACD
- SUGP -0.02
- AIMD 0.01
- Stochastic Oscillator
- SUGP 14.71
- AIMD 60.64
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment. Geographically operates in Hong Kong, and Other foreign countries, with maximum revenue from Kong Kong.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.